Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
1847 Goedeker (GOED)
PaxMedica (PXMD)
Vistas Media Acquisition (VMACU)
Yucaipa Acquisition (YAC.U)
Rackspace Technology, Inc. (RXT)
GO Acquisition (GOAC.U)
BigCommerce Holdings, Inc (BIGC)
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
Priced IPO
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
Pandion Therapeutics, Inc. (PAND)
ALX Oncology Holdings Inc. (ALXO)
Trean Insurance Group, Inc. (TIG)
Relay Therapeutics, Inc. (RLAY)
GoHealth, Inc. (GOCO)
More companies

Applied Molecular Transport Inc. (AMTI)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage biopharmaceutical company leveraging their proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Their proprietary technology platform allows them to exploit existing natural cellular trafficking pathways to facilitate the active transport of therapeutic payloads across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. They believe that their ability to exploit this mechanism is a key differentiator of their approach. They are developing oral biologic product candidates in patient-friendly tablet and capsule forms that are designed for either targeting local gastrointestinal (GI) tissue or entering systemic circulation to precisely address the relevant biology of a disease. They are building a portfolio of oral product candidates based on their technology platform including their lead product candidate, AMT-101, an oral GI-selective interleukin 10 (IL-10) that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). They further plan to initiate Phase 2 clinical trials of AMT-101 in UC and related inflammatory indications. Their technology platform enables them to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and RNA therapeutics, with potentially significant advantages over existing marketed and development-stage drugs.
Industry
PHARMACEUTICAL PREPARATIONS
CEO CFO
Tahir Mahmood Shawn Cross
Employees Founded
49 2010

Contacts

Address: 1 Tower Place, Suite 850, South San Francisco, CA 94080, US

Telephone: 650-392-0420

Web page: https://www.appliedmt.com

IPO information

Expected Date 6/5/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $408.2
Revenues (MM) $0
Net Income (Loss) (MM) $-38.4

Voting

What do you think will happen with the AMTI share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 10
Shares Revised (MM) 11
Expected offer amount (MM) $130
Realized offer amount(MM) $154
Underwriters
BofA Securities/ Jefferies/ SVB Leerink
CO-Managers
-

Sector: Healthcare

Tweets about $AMTI

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats